Date: April 26-29, 2021
Location: Virtual Event
Date: May 4-6, 2021
Location: Virtual Event
We’re celebrating big news from two Cryoport Systems valued clients: bluebird bio and Bristol Myers-Squibb announced FDA approval of their cell therapy Abecma, a personalized immune therapy for patients with multiple myeloma.
While the pandemic continues to disrupt many industries, including regenerative medicine, it’s not all bad news -- in fact, there are likely some bright spots ahead for the industry this year.
©2021 Cryoport Systems, LLC. All rights reserved.
A Leap Forward in Standardizing the Regenerative Medicine Supply Chain – What the New ISO 21973 Guidance Means for Cell and Gene Therapy Developers
Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC